INmune Bio Inc. (INMB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

INmune Bio Inc. (INMB) closed at USD 1.60 on 2026-10-14, a change of -12.1 % over the past year, with a market capitalization of USD 45.79M.

INmune Bio Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

INmune Bio Inc. key figures

Previous close

USD 1.60 (2026-10-14)

1-year change

-12.1 %

Market cap

USD 45.79M

Enterprise value

USD 28.79M

P/E ratio (trailing)

-2.50

P/E ratio (forward)

-3.84

EPS (trailing)

-0.66

EPS (forward)

-0.43

PEG ratio

n/a

Price to book

2.24

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.85

Employees

21

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About INmune Bio Inc.

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for INmune Bio Inc. and compare it with other stocks.